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Protocol
AbstrACt
Introduction For patients with advanced cancer, 
research shows that pain is frequent, burdensome and 
undertreated. Evidence-based approaches to support 
cancer pain management have been developed but 
have not been implemented within the context of 
the UK National Health Service. This protocol is for a 
pragmatic multicentre randomised controlled trial (RCT) 
to assess feasibility, acceptability, effectiveness and cost-
effectiveness for a multicomponent intervention for pain 
management in patients with advanced cancer.
Methods and analysis This trial will assess the 
feasibility of implementation and uptake of evidence-
based interventions, developed and piloted as part of 
the Improving the Management of Pain from Advanced 
Cancer in the Community Programme grant, into routine 
clinical practice and determine whether there are potential 
differences with respect to patient-rated pain, patient pain 
knowledge and experience, healthcare use, quality of life 
and cost-effectiveness. 160 patients will receive either the 
intervention (usual care plus supported self-management) 
delivered within the oncology clinic and palliative care 
services by locally assigned community palliative care 
nurses, consisting of a self-management educational 
intervention and eHealth intervention for routine pain 
assessment and monitoring; or usual care. The primary 
outcomes are to assess implementation and uptake of the 
interventions, and differences in terms of pain severity. 
Secondary outcomes include pain interference, participant 
pain knowledge and experience, and cost-effectiveness. 
Outcome assessment will be blinded and patient-reported 
outcome measures collected via post at 6 and 12 weeks 
following randomisation.
Ethics and dissemination This RCT has the potential 
to signiicantly inluence National Health Service delivery 
to community-based patients with pain from advanced 
cancer. We aim to provide deinitive evidence of whether 
two simple interventions delivered by community palliative 
care nurse in palliative care that support-self-management 
are clinically effective and cost-effective additions to 
standard community palliative care.
trial registration number ISRCTN18281271; Pre-results.
IntroduCtIon
Each year in the UK, 163 000 people die from 
cancer.1 For patients with cancer, research 
shows that pain is frequent, burdensome and 
undertreated.2–5 Over two-thirds (66.4%) of 
these patients will experience pain during 
advanced, metastatic or terminal stages of 
their cancer.5 Many patients with cancer 
spend their last 6 months of life living in the 
community, typically at home, though many 
are admitted as inpatients nearer to death.6 
Barriers to good pain control include inade-
quate support and patient education,7 poor 
assessment and communication,8 and lack of 
access to an adequate prescription and timely 
analgesia.9 A range of approaches have been 
developed that seek to improve the manage-
ment of pain in patients with advanced cancer 
but have not been implemented within the 
strengths and limitations of this study
 Ź This is the irst randomised controlled trial to exam-
ine the effect of a multicomponent complex inter-
vention comprising evidence-based approaches to 
pain management in patients with advanced cancer.
 Ź To optimise the generalisability of the indings, this 
multicentre trial will include patients from palliative 
care services across the UK.
 Ź This trial includes objectives that assess changes 
in pain knowledge and experience as well as pain 
intensity outcomes.
 Ź The pragmatic approach adopted by this trial will 
enable identiication of issues arising from the im-
plementation of a complex intervention in palliative 
care services at transitions between secondary and 
community care in the UK.
 Ź A limitation is that the pragmatic approach may 
have an impact on idelity to the interventions; steps 
have been taken to avoid and monitor contamination 
and measure adherence to interventions. 
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context of the National Health Service (NHS) in the UK. 
Three emerging approaches that address key barriers to 
pain management for patients with advanced cancer are 
outlined, including referral to specialist palliative care, 
self-management of pain and analgesia, and routine 
monitoring of pain.
specialist palliative care
Specialist palliative care aims to relieve suffering and 
improve quality of life for people with advanced diseases, 
such as cancer, who are facing death. For patients 
with advanced cancer, several randomised controlled 
trials (RCTs)10–14 have shown that early access to palliative 
care can improve symptoms, reduce acute hospital admis-
sions, minimise aggressive cancer treatments and enable 
patients to make choices about their end-of-life care, 
including exercising the choice to die at home. Interven-
tions in these trials varied, but common characteristics 
included assessment and several follow-up consultations 
by specialist palliative care teams over a period of 2–3 
months. Where reported, patients were recruited and 
received these interventions about 6 to 14 months before 
their death.10–14 Collectively, these data suggest that a dose 
of three to four palliative care contacts applied about 6 
months before death is associated with better end-of-life 
care. The trials from which this evidence is derived were 
based in North America, and the studies vary widely in 
their definition of what constitutes palliative care services 
and who provides them. These limitations have prevented 
direct translation and implementation of this evidence 
within the context of the UK NHS.
supporting self-management of pain and analgesia
Pain for patients with advanced cancer is a complex 
and dynamic experience.15 Poor knowledge and fearful 
attitudes within patients towards cancer pain and anal-
gesia are associated with reluctance to commence 
opioids, reduced medication adherence and higher 
pain intensity.16 17 Providing information to patients 
with cancer pain and addressing concerns regarding 
pain and analgesia are effective interventions that 
support self-management and lead to improvements 
in pain outcomes.18–22 While evidence supports the 
use of self-management approaches, there remains 
uncertainty on the optimum dose and components of 
a self-management intervention, and how best to imple-
ment these in routine practice.
routine monitoring of pain
Assessing pain and presenting data to physicians prior to 
consultation, who then use it within discussions, signifi-
cantly improves pain outcomes and quality of life for 
patients.23 Assessment alone without ensuring that this is 
seen by prescribing clinicians does not lead to improve-
ments in pain,24 highlighting the need for interventions 
to alert clinicians to patients’ symptoms. Two large RCTs, 
one conducted in the USA25 and one in the Netherlands,26 
have demonstrated improvements in cancer pain when 
combinations of interventions have been evaluated. The 
first compared telephone self-management support from 
nurses combined with automated symptom monitoring, 
with usual care. Significant reductions in pain scores were 
demonstrated over a 12-month period.25 The second 
combined specialist pain consultation with nurse-led 
self-management support and compared this with usual 
care.26 Over an 8-week follow-up period, significant bene-
fits were experienced by intervention patients in pain 
scores and reduction in interference in daily living from 
pain. Similar to education self-management approaches, 
there is uncertainty about the optimum dose, alongside a 
lack of evidence of implementation in the context of the 
UK NHS.
rationale
We have developed a complex intervention consisting 
of three distinct components: (1) referral to community 
palliative care support, (2) a resource to support self-man-
agement of pain and analgesia, and (3) an electronic pain 
monitoring system. We hypothesise that within oncology 
(or related) services, screening and referral of commu-
nity-based patients with pain from advanced cancer to a 
cancer pain pathway, combined with a package of routine 
pain assessment and monitoring using an e-health tool, 
will reduce the extent of pain and psychological distress 
reported by the patient.
We will undertake a multicentre RCT to assess the 
acceptability and feasibility of implementation of the 
complex intervention, its potential cost-effectiveness and 
impact on pain management.
MEthods And AnAlysIs
This trial is the fourth and final project of a National Insti-
tute for Health Research Programme Grant for Applied 
Research (NIHR PGfAR), which consists of interlinked 
studies aiming to improve the management of pain 
from advanced cancer in the community: Improving 
the Management of Pain from Advanced Cancer in the 
CommuniTy (IMPACCT).
The programme follows the Medical Research Council 
Framework guidance for the design and evaluation of 
complex interventions27 and consists of the following 
component projects:
 Ź To design and test a cancer pain pathway that allows 
early intervention and promotes self-management.
 Ź To demonstrate the feasibility of routine cancer pain 
monitoring within the NHS.
 Ź To promote non-medical prescribing and develop the 
role of community pharmacists.
 Ź To establish the feasibility of delivery of our interven-
tion in routine care, and potential effectiveness on 
patient outcomes and cost-effectiveness (which this 
protocol relates to).
Aims
The trial aims to assess the feasibility of implementation 
and uptake of evidence-based interventions, developed 
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and piloted as part of the IMPACCT NIHR PGfAR, into 
routine clinical practice and determine whether there are 
potential differences with respect to (1) patient-rated pain, 
(2) patient pain knowledge and experience, (3) health-
care use, (4) quality of life and (5) cost-effectiveness.
Our intervention, combining usual care and supported 
self-management, including an educational resource and 
pain monitoring, aims:
 Ź To improve the management of cancer pain for palli-
ative care patients who are living at home.
 Ź To enable patients to more easily access support and 
advice, communicate their pain, and obtain timely 
and effective medication.
 Ź To educate patients on tackling cancer pain through 
an educational intervention.
design
This is a pragmatic multicentre RCT to evaluate the feasi-
bility of delivery and implementation of a supported 
self-management intervention into routine clinical prac-
tice in the UK for patients with cancer, which is active 
and incurable; and its potential impact on pain manage-
ment and cost-effectiveness (see figure 1 for a trial flow 
diagram). Qualitative and cost-effectiveness components 
are embedded.
We will aim to recruit 160 participants at the point 
of identification for referral into palliative care and 
follow-up at 6 and 12 weeks. Participants will be 
randomised on a 1:1 basis to receive either usual care 
plus supported self-management, delivered within the 
oncology clinic and palliative care services by locally 
assigned community palliative care nurses, or usual care. 
As part of usual care, all participants will be referred to 
their local palliative care team for pain management.
objectives
Objectives relate to both the feasibility of delivery and 
implementation of interventions into routine practice 
and an assessment of the effectiveness of the intervention:
 Ź Delivery and implementation of the intervention: 
The primary implementation objective is to evaluate 
adherence in terms of the uptake and retention rate 
of each intervention through process evaluation, 
including qualitative study.
 Ź Potential effectiveness of the intervention: The 
primary effectiveness objective is to assess the effec-
tiveness of the intervention compared with usual 
care as measured by pain severity on the Brief Pain 
Inventory (BPI) 12 weeks after randomisation. 
Secondary objectives will assess differences at 6 weeks, 
Figure 1 Trial low diagram.
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patient-rated pain on the 7-point global rating of 
change in pain,28 healthcare use in each arm, patient’s 
pain knowledge and experience, patient’s general and 
cancer-specific quality of life, and cost-effectiveness of 
the interventions.
recruitment, setting and participants
Participants will be identified and recruited in the 
oncology (or related) clinic by the research nurse, in 
consultation with the patient’s clinician/treating team. 
Prior to the start of recruitment into the trial, research 
centres will be required to have obtained local ethical and 
management approvals and undertaken training in the 
intervention and in the trial procedures delivered by the 
central trial team.
To be included in the trial, participants are required to 
meet the eligibility criteria described in table 1.
All patients presenting to clinics with a cancer diagnosis 
of advanced incurable disease will be screened. Data will 
be recorded anonymously to document reasons for ineli-
gibility or decline in participation to monitor trial uptake 
and recruitment progress, and representativeness of the 
trial population.
Patients meeting the eligibility criteria will be 
approached by the research nurse while they attend the 
clinic for their standard follow-up care to confirm eligi-
bility and provide verbal and written details about the 
trial. Patients will be provided with a Participant Infor-
mation Sheet and given as long as they need to consider 
participation in the trial, as well as the opportunity to 
discuss the trial with their family and other healthcare 
professionals. Patients will then be asked whether they 
would be willing to take part in the trial and informed 
consent, and baseline assessments, will be obtained in a 
location convenient for the participant, at their home or 
clinic.
randomisation and blinding
Following confirmation of eligibility, written informed 
consent and completion of baseline assessments, 
participants will be randomised into the trial by the 
research nurse. Randomisation will be performed 
centrally via an automated system at the Clinical Trials 
Research Unit at the University of Leeds. Participants 
will be randomised on a 1:1 basis to receive either usual 
care plus supported self-management or usual care, 
using a computer-generated minimisation programme, 
incorporating a random element, to ensure treatment 
groups are well balanced for the following: average 
pain at baseline on the BPI (4–6, 7–10) and recruiting 
site. The recruiting team are not involved in subse-
quent intervention delivery.
Intervention
Both usual care, and the intervention, usual care plus 
supported self-management will be delivered within the 
oncology clinic and palliative care services by locally 
assigned community palliative care nurses. As part of 
usual care, all participants will be referred to their local 
palliative care team for pain management. Supported 
self-management will consist of an educational interven-
tion ‘Tackling Cancer Pain’ and an e-Health routine pain 
assessment and monitoring intervention ‘Pain Check’. 
Components of the trial intervention are detailed in 
table 2.
Intervention delivery
Training in the use of the interventions will be provided to 
the Community Palliative Care Team prior to the partic-
ipating centres opening to recruitment. Training will be 
provided by the trial researchers based at the University 
of Leeds and involved in the IMPACCT Programme Grant 
working closely with the lead nurse at palliative care sites, 
recruiting sites and the administrative support staff for the 
community team. As part of the training, the Community 
Palliative Care Team will receive instructions for training 
the participants in the interventions, which will include a 
demonstration for the participant on how to log on and 
use PainCheck at the initial visit, and written instructions 
and a contact for any future queries will be provided. 
The participants will receive the educational intervention 
‘Tackling Cancer Pain’ booklet and DVD from the pallia-
tive care team and asked to use it as much and as often as 
they would like.
Table 1 Eligibility criteria
Eligibility 
criteria Details
Inclusion criteria 1. Male or female aged ≥16 years
2. Diagnosis of advanced incurable 
cancer (locally advanced or metastatic) 
Experiencing cancer-related pain (tumour 
or treatment related) with a pain score 
of ≥4 on the ‘average pain’ item of the 
Brief Pain Inventory
3. Has the potential to beneit from pain 
management
4. Expected prognosis of ≥12 weeks
5. Living at home
6. The patient is living in the local 
catchment area for a participating 
hospice
7. The patient is able and willing to 
provide written informed consent
Exclusion criteria 1. Patients who are currently receiving 
or have previously received community 
palliative care support
2. The patient has insuficient literacy, or 
proiciency in English to contribute to the 
data collection required for the research
3. Patients will be excluded if they lack 
capacity to provide informed consent to 
this trial
4. Patients with dominant chronic pain 
that is not cancer related (tumour or 
treatment)
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Table 2 Overview of trial intervention components
Intervention 
components Description
Usual care (received by 
both groups)
Referral to community palliative care: Screening of patients with pain from advanced cancer will be implemented by optimising entry points to the care pathway via 
oncology (or related) outpatient services and will facilitate the low of patients to appropriate pain support as and when required. Oncology research nurses will refer 
trial participants to the local community palliative care team at which point the locally assigned palliative are nurse will endeavour to arrange an initial visit/appointment 
with participant within 1 week of randomisation.
Appointment into palliative care: This will take place by a locally assigned community palliative care nurse. Routine practice will be followed, including an assessment 
of the participants’ other palliative care needs. For those participants allocated to receive usual care and supported self-management, the nurse will be trained in the 
trial interventions and will introduce and deliver the trial interventions described below, alongside their usual care.
Patient self-
management 
educational intervention
Name: ‘Tackling Cancer Pain—A toolkit for patients and families’
Why: ‘Tackling Cancer Pain—A toolkit for patients and families’ is based on a review of current evidence and on focus group interviews with patients, family caregivers 
and health professionals working in specialist palliative care.36 37 Providing information to patients with cancer pain and addressing concerns regarding pain and 
analgesia are effective interventions that support self-management and lead to improvements in pain outcomes.18–22
What: ‘Tackling Cancer Pain—A toolkit for patients and families’ is formatted as a loose-leaf ring binder with an accompanying DVD. It consists of ive sections: 
Understanding Cancer Pain; Using Drugs to Manage Pain; Additional Approaches to Managing Pain; Talking About Pain; Getting More Help. Each section contains 
information and self-directed learning activities along with sources of further information. It is written in easily understandable lay persons’ language. The booklet 
and DVD contain essentially the same information but in different formats and are structured so that they can be used independently by patients or family members. 
Guidance is given in each chapter about how to use the information presented. Step-by-step tuition is provided on non-pharmacological pain relief measures such as 
relaxation and visualisation, and on how to initiate and conduct conversations about pain with health professionals.
Who provides: ‘Tackling Cancer Pain—A toolkit for patients and families’ will be introduced to participants by their trained locally assigned community palliative care 
nurse within 1 week of randomisation and subsequent participant questions on the booklet and DVD can be addressed to this palliative care nurse. Training on the 
content and use of ‘Tackling Cancer Pain—A toolkit for patients and families’ will be provided by the trial researchers. The training will include written instructions on 
how to train participants in the interventions and a contact for any future queries.
How: ‘Tackling Cancer Pain—A toolkit for patients and families’ is accessed by the patient or their family by reviewing the information contained in the loose-leaf ring 
binder and on the accompanying DVD.
Where: The expectation is that ‘Tackling Cancer Pain—A toolkit for patients and families’ will be accessed by patients and their families while in the community setting 
(ie, in their usual place of residence).
When and how much: Participants are not provided with details of schedule, duration, intensity or dose for using ‘Tackling Cancer Pain—A toolkit for patients and 
families’. Instead, participants are free to use the resource as they would like.
Modiications: On-going
How well (planned): Intervention data collection (baseline) will identify that the patient received the intervention. Semistructured end-of-trial interviews with patients and 
health professionals will also inform how the intervention is used.
How well (actual): On-going
Continued
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Intervention 
components Description
e-Health intervention 
for routine pain 
assessment and 
monitoring in patients 
with advanced cancer
Name: ‘PainCheck’
Why: The process of assessing pain and presenting data to physicians prior to consultation, who then use it within discussions, signiicantly improves pain outcomes 
and quality of life for patients.23 PainCheck was developed to facilitate this communication by enabling patients to routinely report and share pain data for health 
professionals to access. Its development was informed by patient, caregiver and health professional involvement.31–35
What: PainCheck allows patients to record their pain and gives them access to personalised pain management advice. Patients are asked to answer various questions 
about their pain including providing a description of their pain, rating current pain intensity and intensity in the last 12, pain control, interference and sleep. Items were 
taken from the Brief Pain Inventory38 and Coping Strategies Questionnaire.39 Patients are asked about pain management techniques, which of these were helpful and 
how likely they are to try them in the future. Various question response options are used including multiple choice, numerical (0–10 or 0–6) slider scales and free text. 
After completion, patients are provided with a summary of their results and suggestions of pain management techniques they may want to try in the future. Health 
professionals can log in to PainCheck and view all patients registered on PainCheck and see who have completed reports. They are then able to select a patient 
and view responses to individual questions. Health professionals are presented with a graph that tracks patients’ current pain and pain in the last 12 hours over time. 
Patients are given a ‘red lag’ in the health professional system if they reach certain thresholds for current pain and pain control. After reading the patient report, 
health professionals can decide what action, if any, they would like to take as a result. Health professionals have the option to contact patients through PainCheck 
to provide information and advice. PainCheck was developed using QTool. QTool is a secure online system, which can be integrated in real time with the electronic 
patient records, enabling collection of patient-reported information (such as symptoms, treatment side effects, pre-clinic questions, satisfaction surveys). QTool was 
developed by the collaborative efforts of multiple research groups based at the University of Leeds pooling approximately £400 000 of research funding. The current 
version of PainCheck does not use linkage with existing electronic clinical record systems; instead, PainCheck is currently run as a standalone intervention.
Who provides: PainCheck will be introduced to participants by their locally assigned community palliative care nurse within 1 week of randomisation. Training on using 
PainCheck with patients will be provided by trial researchers to community palliative care nurses. Training will include instructions for training the participants in the 
interventions, which will include a demonstration for the participant on how to log on and use the Routine Pain Assessment and Monitoring system at the initial visit.
How: PainCheck will be introduced to patients by their locally assigned community palliative care nurse. The introduction will involve participants logging in to the 
system (using unique login details that will be provided by the community palliative care nurse) and working through an assessment using the instruction lealet 
as a guide. The palliative care nurse will oversee the participant’s irst access and use of PainCheck and will provide additional support/guidance if necessary. At 
induction into the system, participants will be made aware that PainCheck should not be used to request urgent or emergency help; where urgent or emergency help 
is required participants are told to contact the emergency services. On visiting PainCheck, participants are reminded, by use of an on-screen message, that should 
they need immediate medical attention they should call the emergency services. If they require urgent medical advice, they are advised to contact their doctor, nurse 
or pharmacist. This reminder is provided near the beginning and at the end of each PainCheck session. Following an introduction to PainCheck, participants (or a 
person submitting responses on a participant’s behalf) will be expected to complete pain assessments without the community palliative care nurse present. Each pain 
assessment asks for clariication of who is entering data (ie, a patient, or someone on their behalf), which is relected in reports when viewed by health professionals. 
Based on reports submitted by participants, the PainCheck system can provide two types of email alert to health professionals: high priority (generated immediately 
when a patient submits a report indicating high pain and/or low levels of control) and low priority (a weekly email sent when participants are interacting with PainCheck 
but reporting very low levels of pain or no pain). After reviewing reports submitted to PainCheck, a health professional is asked to record in the system what action 
they took: (1) no further action, (2) contact another health professional, (3) contact the patient and (4) other. PainCheck can be accessed by patients and health 
professionals using any device that enables access to the internet (eg, using laptop, smartphone or tablet computers).
Where: The expectation is that PainCheck will be accessed by patients or their families while in the community setting, which could include usual place of residence or 
alternative chosen location.
When and how much: Following the introduction of routine completion of PainCheck in the community, participants will be encouraged to use the system at least 
once a day, with additional entries being encouraged when/if pain events occur. PainCheck will be available to participants until 14 days after their 12-week follow-up 
assessment. Participants are notiied in writing that access to PainCheck will be ending.
Modiications: On-going
How well (planned): Intervention data collection (at baseline) will conirm that a patient received details to access PainCheck. Data captured by PainCheck will provide 
insight into the frequency of use by patients, alongside identifying interaction between health professionals and patients that occurs through PainCheck (ie, messages 
sent to patients by health professionals). Semistructured end-of-trial interviews with patients and health professionals will inform how the intervention is used.
How well (actual): On-going
Table 2 Continued 
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Measuring adherence to the interventions
We will record steps taken to ensure consistency in 
the delivery of the interventions—including training 
sessions with palliative care nurses such as additional 
training on delivery of the routine pain assessment 
and monitoring intervention for new staff. Monitoring 
adherence to the educational and routine pain assess-
ment and monitoring interventions will involve the 
participants, the locally assigned community palliative 
care nurse and information directly from the routine 
pain assessment and monitoring tool.
Contamination
The risk of contamination between the two trial arms will 
be minimal as the educational intervention and routine 
pain monitoring will be made available only to partici-
pants allocated to the supported self-management arm 
of the trial, and there is little opportunity for partici-
pants in either trial arms to meet and discuss treatment. 
The importance of contamination was included in site 
training, so site teams are made aware not to share 
materials. We will record the number of contacts in 
community palliative care and the staff involved in the 
care to explore the potential for contamination. The 
number of Tackling Cancer Pain booklets and accompa-
nying DVDs provided to each hospice will be monitored 
against the number of participants allocated to receive 
this intervention to ensure these are not being used 
for other patients. The online pain monitoring system 
can only be used by participants allocated to the inter-
vention who are assigned a trial specific username and 
password obtained from the research team. There is no 
risk of contamination in the recruiting clinics as inter-
vention delivery takes place in the community palliative 
care setting; notification of trial referrals to the pallia-
tive care team will clearly document the participants’ 
randomisation allocation. We will monitor the timing 
at which patients are referred into palliative care and 
documentation of previous palliative care discussions.
Assessments and data collection
Required data, assessment tools, collection time points 
and processes are summarised in table 3 and detailed 
further in online supplementary appendix 1.
Clinical data
Clinical follow-up data will be obtained directly from 
participant’s hospital and palliative care records by the 
research nurse and palliative care team up to 12 weeks 
post-randomisation. Data recorded will include health-
care use, including referral and contacts with commu-
nity palliative care, hospital attendances and admissions, 
prescription medication use and use of pain relief, and 
related unexpected serious adverse events. All-cause 
mortality will be collected continuously throughout the 
trial up until the point of the final participant’s 12-week 
follow-up assessment. Details of participants and health 
professional’s use of PainCheck will be obtained directly 
from the PainCheck system via an export into Microsoft 
Excel in comma separated values (CSV) format.
Participant-completed data
Patient-reported outcome measures are collected via post at 
6 and 12 weeks following randomisation. Where required, 
the trial researcher will collect this data by telephone.
Participant questionnaires are posted at weeks 5 and 11 
for each follow-up time point, following which the trial 
researcher will contact the participant by telephone to 
check receipt and offer completion of the questionnaires 
over the phone if the participant wishes to do so. If the 
questionnaire pack is not completed over the phone, 
and questionnaires are not returned by post 1 week 
later, the trial researcher will telephone the participant 
again to remind them. If contact cannot be made, the 
trial researcher will continue to attempt to contact the 
participants up to weeks 8 and 14 for each follow-up time 
point. If the trial researcher becomes unblinded to treat-
ment allocation, this will be recorded and the subsequent 
follow-up telephone call at 12 weeks will be conducted by 
an alternative researcher.
Prior to contacting the participant for the follow-up visits 
or to post the questionnaires, the participants’ survival 
status will be established by the central research team via 
the general practitioner or the oncology research nurse.
At the end of the 12-week follow-up period, participants 
will receive a thank you letter through the post (along 
with their 12-week questionnaires).
Qualitative interviews
A subsample of 15 consenting usual care plus supported 
self-management arm participants will be invited to take 
part in a semistructured interview at approximately 
6 or 12 weeks post-randomisation. The interview will 
explore what participants felt about referral to commu-
nity palliative care, how they used the Tackling Cancer 
Pain booklet/DVD and PainCheck, and if they found the 
interventions useful. A proportion of participants will be 
interviewed at 6 weeks to ensure a representative sample 
considering loss to follow-up for illness or death by 12 
weeks. Participants will be selected based on their age, 
gender, community palliative care team (hospice) and 
level of PainCheck use.
A sample of 15 palliative care nurses will be invited 
to take part in a semistructured end-of-trial interview in 
order to explore their thoughts on the interventions, if 
they found the interventions useful, how the interven-
tions impacted on pain management and their clinical 
practice, and potential within-trial contamination. Nurses 
will be asked to sign a consent form before the interview 
begins and will be selected based on their team (hospice), 
level of PainCheck use and the number of trial partici-
pants they have seen.
Both interviews will be conducted by a different trial 
researcher to that involved in other data collection, will 
last approximately 60 min and will be audio-recorded and 
transcribed verbatim.
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Health service delivery data
For all participating sites, the central research team will 
collect details of current service provision to help under-
stand the local services and standard care pathways for the 
study population. This will include data collection to explore 
who is responsible for identifying patients as requiring pain 
management support and/or a referral to palliative care, 
who is responsible for performing referrals and how closely 
the oncology (or related) clinic staff work with their hospital 
and local community palliative care teams.
Table 3 Summary of assessment type, completers and timing
Assessment
Who to complete/
action
Timeline (weeks post-randomisation)
Screening Baseline Week 6 Week 12
Baseline data (collected from case notes)
  Demographic data, eligibility, written informed 
consent
Research nurse X
  Background and medical history Research nurse X
  Referral to local participating community palliative 
care team
Research nurse X
  Schedule initial appointment within 1 week; deliver 
usual care OR usual care and introduction of trial 
interventions as determined by randomisation 
allocation
Palliative care team X
Clinical follow-up data (collected from case notes or hospice system for example, SystmOne)
  Use of Intervention and usual care details Palliative care team X
  All-cause mortality Palliative care team X
  Serious adverse event reporting Palliative care team Ongoing reporting
Clinical follow-up data (collected from case notes, hospital system for example, SystmOne and PPM database)
  Healthcare use Research nurse X
  Pain medication Research nurse X X
  Date of referral to community palliative care, 
no and details of contacts
Research nurse X
  All-cause mortality Research nurse X
  Serious adverse event reporting Research nurse Ongoing reporting
Patient-completed questionnaires (completed in clinic at baseline and at home/over telephone for follow-up visits)
  BPI assessment Trial researcher X X X
  7-point global rating change of pain Trial researcher X X
  Healthcare use (Health Economics questionnaire) Trial researcher X X X
  Patient Pain Questionnaire40 Trial researcher X X X
  EQ-5D41 Trial researcher X X X
  EORTC QLQ-C3042 Trial researcher X X X
Clinical follow-up data (collected via GP practice)
  Date of referral to community palliative care Trial researcher Ongoing reporting
  Survival status Trial researcher/Leeds 
Institute of Clinical 
Trials Research 
Ongoing reporting
Routine monitoring data
  Uptake (patients and palliative care nurse) and 
patient-reported pain diaries
Trial researcher* Ongoing reporting
  Qualitative participant interviews Trial researcher* ~6 or 12 weeks post-
randomisation
  Participant qualitative palliative care nurse end of 
trial interviews
Trial researcher* End of trial
*Conducted through a different trial researcher involved in patient-completed questionnaire follow-up and clinical follow-up.
BPI, Brief Pain Inventory; EORTC, European Organization for Research and Treatment of Cancer; GP, general practitioner.
 o
n
 18 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021965 on 22 March 2018. Downloaded from 
9Allsop MJ, et al. BMJ Open 2018;8:e021965. doi:10.1136/bmjopen-2018-021965
Open Access
sample size
To address the potential effectiveness of the interven-
tion the power calculation is based on the difference in 
mean pain severity (BPI) at 12 weeks. With 80% power 
and a two-sided type I error rate of 0.05, we estimate that 
128 patients (64 per group) will be required to detect a 
moderate intervention effect size of 0.529 between the 
intervention and control arm. In addition, a relative 
reduction of ≥30% in pain severity (BPI) is an accepted 
threshold for clinically significant improvement in pain 
trials.30 Results from a previous study involving automated 
symptom modelling found a 27% difference in such 
improvement rates at 12 weeks.25 Our estimated sample 
size will therefore also provide 80% power to detect a 
similar difference in rate. As our patient sample is drawn 
from a generally frail population, we have allowed for 
an attrition rate of 20% and therefore aim to recruit 
160 participants (80 per group). The trial is expected to 
recruit from four to five participating centres that will be 
selected due to their large oncology (or related) clinics.
data analysis
There are no planned interim analyses; outcome data will 
be analysed once only. All analyses will be conducted on 
the intent-to-treat population, in which all participants 
will be included in the analysis according to allocation, 
regardless of non-compliance with the intervention. An 
overall two-sided 5% significance level will be used for all 
statistical endpoint comparisons. Details of all analysis are 
provided in box 1.
PAtIEnt And PublIC InvolvEMEnt
The IMPACCT research programme comprises four 
work streams. The first three work streams, running in 
parallel, sought to understand and improve current 
cancer pain management at the levels of the patient 
and their caregiver, health professional and healthcare 
system. Across these three work streams, extensive user 
engagement with patients, caregivers and health profes-
sionals occurred, informing an understanding of their 
priorities, experience and preferences relating to cancer 
pain management. Part of this work involved the devel-
opment and piloting of interventions used in the trial, 
including assessment of their acceptability, and informed 
the design of the trial, its research question and outcome 
measures. The research programme also has a patient and 
public involvement (PPI) group, comprising patients with 
cancer and caregivers of those with cancer. PPI represen-
tatives are co-investigators on the research programme, 
contributors at all quarterly programme management 
meetings and members of the trial steering group. The 
latter enabled PPI representatives to inform the recruit-
ment processes and conduct of the trial. For example, 
it was decided that due to participants having advanced 
disease, information sheets should provide contact details 
to enquire about study findings rather than active dissem-
ination by the research team. PPI involvement has been 
box 1 data analysis plan for primary and secondary 
outcomes, health economic analysis and qualitative data
Analysis activities
Primary outcomes
 Ź To assess the primary implementation outcome, the proportion of 
participants receiving each intervention, at least one intervention 
and all interventions will be summarised overall and by recruiting 
site along with 95% CIs.
 Ź To assess the primary effectiveness outcome, pain severity (Brief 
Pain Inventory, BPI), we will it a linear mixed-effects regression 
model with repeated measures (6 and 12 weeks). The model will 
contain centre random effect, and ixed effects for intervention 
group, research centre, baseline score, time, and intervention 
group by time interaction. Similarly, a logistic mixed-effects regres-
sion model will be used to assess the proportion of participants 
with ≥30% reduction in pain severity.
secondary outcomes
 Ź The secondary outcomes BPI interference, participant’s pain 
knowledge and experience, EQ-5D and European Organization for 
Research and Treatment of Cancer (EORTC) QLQ-C30 will be as-
sessed using a linear mixed-effects regression model with repeated 
measures as per the primary outcome.
 Ź The 7-point global rating of change in pain, healthcare use and safe-
ty data will be summarised.
 Ź Exploratory subgroup analysis will be conducted, differentiating 
participants in the intervention arm who were engaged in the use 
of PainCheck versus those who were not. Descriptive statistics will 
be used to present the primary outcome at each time point for each 
subgroup.
Missing data
 Ź Reasons for attrition and missing data will be summarised along 
with reason, following the classiication set out in the MORECare 
statement43: attrition due to death, illness or at random; with addi-
tional reason due to participant withdrawal.
 Ź The pattern of missing data according to participant characteristics 
will be investigated to inform the multiple imputation approach and 
the assumptions of Missing At Random and Missing Not At Random.
 Ź Regression analysis will handle missing data due to attrition by test-
ing results from different methods of imputation, including multi-
ple imputation44 in the primary analysis, allowing all participants in 
the intention-to-treat population to be included, and analysis to the 
availability of data in sensitivity analysis. This will allow us to test the 
trial conclusions under different assumptions and biases introduced 
through missing data.
health economic analysis
 Ź The economic evaluation will follow the National Institute for Health 
and Care Excellence reference case45 and hence will be a cost-util-
ity analysis presenting cost  per incremental quality-adjusted life 
year  (QALY) from the perspective of the healthcare and personal 
social services provider. It will be informed by earlier work of the 
research team.46
 Ź The evaluation will combine trial-based and model-based analyses. 
Trial data will be analysed to yield within-trial cost-utility results. 
Participants will complete the utility measures (EQ-5D and EORTC-
8D, the latter derived from the QLQ-C30)47 at baseline and follow-up 
along with a resource use questionnaire. The EQ-5D values will be 
used in the primary analysis with supplementary analyses pre-
sented based on the EORTC-8D and pain rating item from the BPI. 
Survival data will be combined with utility data to calculate QALYs 
and resource use costed using national resources (eg, National 
Continued
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central to all research programme activities, informing 
our approach to patient, caregiver and health profes-
sional engagement prior to and during the trial.
dIsCussIon
This trial will conclude a 5-year programme of research 
funded by the NIHR PGfAR Programme. The wider 
aim of the programme, IMPACCT, is to reduce distress 
from cancer pain in palliative care patients and reduce 
the impact on the NHS of avoidable admissions for 
cancer pain. We believe that our RCT has the potential 
to significantly influence NHS service delivery to commu-
nity-based patients with pain from advanced cancer. We 
aim to provide definitive evidence of whether two simple 
interventions delivered by community palliative care 
nurse in palliative care that support self-management are 
clinically and cost-effective additions to standard commu-
nity palliative care. We are conducting a detailed process 
evaluation that will inform an implementation strategy for 
the wider NHS if we find a benefit for intervention. One 
of our interventions, ‘Tackling Cancer Pain—A toolkit 
for patients and families’ addresses all the information 
recommendations in the National Institute for Health 
and Care Excellence guidance on ‘Opioids in Palliative 
Care’ and was runner-up in the British Medical Associa-
tion Patient Education awards 2016. Our electronic pain 
monitoring system ‘PainCheck’ is underpinned by signif-
icant development work,31–35 which explores engagement 
by patient and healthcare professionals. PainCheck offers 
a potentially time-efficient and cost-efficient way for busy 
community palliative care teams to monitor patients with 
cancer pain and respond when needed.
Ethics and dissemination
A favourable ethical opinion was obtained from the NHS 
National Research Ethics Service Committee Yorkshire & 
The Humber—Leeds East, reference number 15/YH/0235. 
The trial opened and recruited the first participant in 
October 2015. Screening, recruitment and implementa-
tion were monitored on a monthly basis. After 6 months 
of recruitment and after 13 patients had been recruited, it 
was apparent that the trial design needed to be changed to 
ensure the trial is embedded in existing NHS care pathways. 
A substantial amendment was made to remove the concept 
of ‘early screening and referral’ to allow identification at 
point of referral. The rationale for this was that patients 
were already being referred to community palliative care 
services for pain management support when needed. The 
trial is sponsored by the University of Leeds (Faculty Head of 
Research and Innovation Support, Faculty of Medicine and 
Health Research Office, University of Leeds), managed by 
the Clinical Trials Research Unit at the University of Leeds 
and supported by a Trial Management Group (TMG) and 
Trial Steering Committee (TSC). The TMG is composed of 
individuals responsible for the day-to-day management of 
the trial, including the PI (MIB), statisticians, trial manager, 
research nurse and researchers. The TSC includes external 
experts who will provide overall supervision for a trial on 
behalf of the Trial Sponsor and Trial Funder.
The following organisations have given research 
governance approval for the trial: Diana Princess of 
Wales Hospital, Grimsby; Care Plus Group, Grimsby; 
Nottingham City Hospital, Nottingham; Nottingham City-
care, Nottingham; St James University Hospital, Leeds; St 
Gemma’s Hospice, Leeds; Wheatfields Hospice, Leeds; 
Wakefield Hospice, Wakefield; York Hospital, York; St 
Leonards Hospice, York; Bradford Royal Infirmary, Brad-
ford; Marie Curie Hospice, Bradford; Huddersfield Royal 
Infirmary, Huddersfield; Kirkwood Hospice, Hudders-
field; Churchill Hospital, Oxford; Sobell House, Oxford; 
Scarborough General Hospital, Scarborough; St Cather-
ine’s Hospice, Scarborough.
Data will be collected and retained in accordance with 
the Data Protection Act 1998 (and successor legislation). 
Trial documents (paper and electronic) will be retained 
in a secure location for 5 years after trial completion. 
To support dissemination of our findings, we will work 
box 1 Continued
Health Service reference costs, personal social services research 
unit costs). The development and implementation of the interven-
tions will be costed following consultation with the trial researchers 
leading each Improving the Management of Pain from Advanced 
Cancer in the Community programme work stream. The within-trial 
analysis will present (where appropriate) incremental cost-effec-
tiveness ratios (ICERs) for the interventions versus usual care with 
ICERs below £20 000 usually indicative of cost-effectiveness. Non-
parametric bootstrapping and deterministic sensitivity analyses will 
be conducted to estimate the level of uncertainty around the ICERs.
 Ź In parallel, a simple decision-analytic Markov model will be devel-
oped. This will be developed according to best practice48 and yield 
cost per QALY estimates. The model will allow the extrapolation of 
expected costs and beneits beyond the trial period. It will also allow 
a more in-depth exploration of uncertainty in the ICERs and a more 
lexible exploration of scenario sensitivity analyses.
Process evaluation
 Ź Quantitative analysis will summarise delivery and implementation of 
the intervention according to:
  Palliative care nurse use of interventions, including the number 
of participants seen by each palliative care nurse by trial arm to 
explore the level of clustering and potential for contamination by 
the nurse.
  Training and supervision for intervention delivery.
  Participant uptake, including a low diagram to depict uptake and 
usage according to the initial palliative care visit and subsequent 
use of PainCheck.
 Ź Qualitative interview analysis: Interview transcripts will be anal-
ysed using framework analysis49 to draw out key themes from the 
data. The framework analysis process involves ive key stages: (1) 
Familiarisation—getting an overview of the issues raised during the 
interviews; (2) Identifying a thematic framework—making notes 
on the key issues discussed; (3) Indexing—applying the thematic 
framework to the data; (4) Charting—moving data from individual 
interviews and putting sections into the framework; (5) Mapping and 
interpretation—the researcher attempts to make sense of the data 
and interpret the key themes and issues discussed.
 o
n
 18 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021965 on 22 March 2018. Downloaded from 
11Allsop MJ, et al. BMJ Open 2018;8:e021965. doi:10.1136/bmjopen-2018-021965
Open Access
with local and national patient advocacy groups (linking 
to public and patient involvement co-applicants on the 
wider programme) to explain our work and encourage 
wider adoption of our findings. We will also disseminate 
through academic papers and presentation at national 
and international clinical meetings.
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